A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.
 

Jennifer Woyach, MD, associate professor at The Ohio State University, discusses current clinical trials going on in the chronic lymphocytic leukemia space that are most likely to impact the treatment landscape.

The analysis evaluated emerging mutations in patients with relapsed/refractory acute myeloid leukemia receiving gilteritinib therapy in the phase 3 ADMIRAL study.
 

A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.
 

A cohesive overview of the classes of agents used to treat patients with opioid-induced constipation.

Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.
 

Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).

Sarah A. Spinler highlights common factors that are responsible for drug shortages in the United States and points out available resources that can help educate stakeholders on current drug shortages.

A discussion on when to implement bevacizumab into the treatment plan and the rationale for using PARP inhibitors to treat individuals with ovarian cancer.

Rite Aid’s solution will allow pharmacists to make responsible dispensing decisions by navigating PDMPs.

Studying individuals’ genomes can help influence how different medications work for a patient, avoid harmful adverse drug reactions, and allow scientists to develop personalized medicines for patients with a wide range of diseases and disorders.

Top articles of the week from Specialty Pharmacy Times.